Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms

Human Molecular Genetics

Volumn 17, Issue 13, 2008, Pages 2006-2017

  Pymar, Louis S ^a   Platt, Fiona M ^a   Askham, Jon M ^a   Morrison, Ewan E ^a   Knowles, Margaret A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; ASPARTIC ACID; CYSTEINE; HAMARTIN; HISTIDINE; ISOLEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MESSENGER RNA PRECURSOR; PHENYLALANINE; SERINE; THREONINE; TUBERIN;

AMINO ACID SUBSTITUTION; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CARCINOGENESIS; CHROMOSOME 9Q; CONTROLLED STUDY; GENE DELETION; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; MOLECULAR MECHANICS; NONSENSE MUTATION; PREDICTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STABILITY; RNA SPLICING; SOMATIC MUTATION; TRANSITIONAL CELL CARCINOMA;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 9; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION; HUMANS; MUTATION, MISSENSE; PROTEIN BINDING; RNA SPLICING; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 45749119969     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddn098     Document Type: Article

References (76)

1. Gomez, M., Sampson, J. and Whittemore, V. (1999) The Tuberous Sclerosis Complex. Oxford University Press.
2. van Slegtenhorst, M., de Hoogt, R., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., van den Ouweland, A., Halley, D., Young, J. et al. (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science, 277, 805-808.
3. Consortium. (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European Chromosome 16 Tuberous Sclerosis Consortium. Cell, 75, 1305-1315.
4. Cheadle, J.P., Reeve, M.P., Sampson, J.R. and Kwiatkowski, D.J. (2000) Molecular genetic advances in tuberous sclerosis. Hum. Genet., 107, 97-114.
5. Jones, A.C., Daniells, C.E., Snell, R.G., Tachataki, M., Idziaszczyk, S.A., Krawczak, M., Sampson, J.R. and Cheadle, J.P. (1997) Molecular genetic and phenotypic analysis reveals differences between TSCI and TSC2 associated familial and sporadic tuberous sclerosis. Hum. Mol. Genet., 6, 2155-2161.
6. Povey, S., Burley, M.W., Attwood, J., Benham, F., Hunt, D., Jeremiah, S.J., Franklin, D., Gillett, G., Malas, S., Robson, E.B. et al. (1994) Two loci for tuberous sclerosis: One on 9q34 and one on 16p13. Ann. Hum. Genet., 58, 107-127.
7. Knudson, A.G., Jr (1971) Mutation and cancer: Statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA, 68, 820-823.
8. Henske, E.P., Scheithauer, B.W., Short, M.P., Wollmann, R., Nahmias, J., Hornigold, N., van Slegtenhorst, M., Welsh, C.T. and Kwiatkowski, D.J. (1996) Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am. J. Hum. Genet., 59, 400-406.
9. Niida, Y., Stemmer-Rachamimov, A.O., Logrip, M., Tapon, D., Perez, R., Kwiatkowski, D.J., Sims, K., MacCollin, M., Louis, D.N. and Ramesh, V. (2001) Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am. J. Hum. Genet., 69, 493-503.
10. Ramesh, V. (2003) Aspects of tuberous sclerosis complex (TSC) protein function in the brain. Biochem. Soc. Trans., 31, 579-583.
11. Plank, T.L., Yeung, R.S. and Henske, E.P. (1998) Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res., 58, 4766-4770.
12. Johnson, M.W., Emelin, J.K., Park, S.H. and Vinters, H.V. (1999) Co-localization of TSC1 and TSC2 gene products in tubers of patients with tuberous sclerosis. Brain Pathol., 9, 45-54.
13. Hodges, A.K., Li, S., Maynard, J., Parry, L., Braverman, R., Cheadle, J.P., DeClue, J.E. and Sampson, J.R. (2001) Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Hum. Mol. Genet., 10, 2899-2905.
14. Kwiatkowski, D.J. and Manning, B.D. (2005) Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet., 14 (Spec No. 2), R251 -R258.
15. Inoki, K., Li, Y., Xu, T. and Guan, K.L. (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes. Dev. 17, 1829-1834.
16. Tee, A.R., Manning, B.D., Roux, P.P., Cantley, L.C. and Blenis, J. (2003) Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol., 13, 1259-1268.
17. Adachi, H., Igawa, M., Shiina, H., Urakami, S., Shigeno, K. and Hino, O. (2003) Human bladder rumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. J. Urol., 170, 601-604.
18. Edwards, J., Duncan, P., Going, J.J., Watters, A.D., Grigor, K.M. and Bartlett, J.M. (2002) Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J. Pathol., 196, 380-385.
19. Hornigold, N., Devlin, J., Davies, A.M., Aveyard, J.S., Habuchi, T. and Knowles, M.A. (1999) Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene, 18, 2657-2661.
20. Cairns, P., Shaw, M.E. and Knowles, M.A. (1993) Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene, 8, 1083-1085.
21. Habuchi, T., Devlin, J., Elder, P.A. and Knowles, M.A. (1995) Detailed deletion mapping of chromosome 9q in bladder cancer: Evidence for two tumour suppressor loci. Oncogene, 11, 1671-1674.
22. Simoneau, M., Aboulkassim, T.O., LaRue, H., Rousseau, F. and Fradet, Y. (1999) Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene 18, 157-163.
23. van Tilborg, A.A., Groenfeld, L.E., van der Kwast, T.H. and Zwarthoff, E.C. (1999) Evidence for two candidate turnout suppressor loci on chromosome 9q in transitional cell carcinoma (TCC) of the bladder but no homozygous deletions in bladder turnout cell lines. Br. J. Cancer, 80, 489-494.
24. Knowles, M.A., Habuchi, T., Kennedy, W. and Cuthbert-Heavens, D. (2003) Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res., 63, 7652-7656.
25. Au, K.S., Williams, A.T., Roach, E.S., Batchelor, L., Sparagana, S.P., Delgado, M.R., Wheless, J.W., Baumgartner, J.E., Roa, B.B., Wilson, C.M. et al. (2007) Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet. Med., 9, 88-100.
26. Jansen, F.E., Braams, O., Vincken, K.L., Algra, A., Anbeek, P., Jennekens-Schinkel, A., Halley, D., Zonnenberg, B.A., van den Ouweland, A., van Huffelen, A.C. et al. (2007) Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations. Neurology, 70, 908-915.
27. Zhang, H., Nanba, E., Yamamoto, T., Ninomiya, H., Ohno, K., Mizuguchi, M. and Takeshita, K. (1999) Mutational analysis of TSC1 and TSC2 genes in Japanese patients with tuberous sclerosis complex. J. Hum. Genet. 44, 391-396.
28. Yamashita, Y., Ono, I., Okada, S., Wataya-Kaneda, M., Yoshikawa, K., Nishizawa, M., Hirayama, Y., Kobayashi, E., Seyama, K. and Hino, O. (2000) Analysis of all exons of TSC1 and TSC2 genes for germline mutations in Japanese patients with tuberous sclerosis: Report of 10 mutations. Am. J. Med. Genet., 90, 123-126.
29. Astrinidis, A., Senapedis, W. and Henske, E.P. (2006) Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner. Hum. Mol. Genet., 15, 287-297.
30. Henikoff, S. and Henikoff, J.G. (1992) Amino acid substitution matrices from protein blocks. Proc. Natl Acad Sci. USA, 89, 10915-10919.
31. Benvenuto, G., Li, S., Brown, S.J., Braverman, R., Vass, W.C., Cheadle, J.P., Halley, D.J., Sampson, J.R., Wienecke, R. and DeClue, J.E. (2000) The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene, 19, 6306-6316.
32. Chong-Kopera, H., Inoki, K., Li, Y., Zhu, T., Garcia-Gonzalo, F.R., Rosa, J.L. and Guan, K.L. (2006) TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J. Biol. Chem., 281, 8313-8316.
33. Goncharova, E.A., Goncharov, D.A., Eszterhas, A., Hunter, D.S., Glassberg, M.K., Yeung, R.S., Walker, C.L., Noonan, D., Kwiatkowski, D.J., Chou, M.M. et al. (2002) Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem., 277, 30958-30967.
34. Kwiatkowski, D.J., Zhang, H., Bandura, J.L., Heiberger, K.M., Glogauer, M., el-Hashemite, N. and Onda, H. (2002) A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet., 11 525-534.
35. Onda, H., Crino, P.B., Zhang, H., Murphey, R.D., Rastelli, L., Gould Rothberg, B.E. and Kwiatkowski, D.J. (2002) Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol. Cell. Neurosci., 21, 561-574.
36. Buratti, E., Chivers, M., Kralovicova, J., Romano, M., Baralle, M., Krainer, A.R. and Vorechovsky, I. (2007) Aberrant 5′ splice sites in human disease genes: Mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res., 35, 4250-4263.
37. Cartegni, L. and Krainer, A.R. (2002) Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet., 30, 377-384.
38. Nakai, K. and Sakamoto, H. (1994) Construction of a novel database containing aberrant splicing mutations of mammalian genes. Gene, 141, 171-177.
39. Nellist, M., van Slegtenhorst, M.A., Goedbloed, M., van den Ouweland, A.M., Halley, D.J. and van der Sluijs, P. (1999) Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin. J. Biol. Chem., 274, 35647-35652.
40. Wei, J., Li, P., Chiriboga, L., Mizuguchi, M., Yee, H., Miller, D.C. and Greco, M.A. (2002) Tuberous sclerosis in a 19-week fetus: immunohistochemical and molecular study of hamartin and tuberin. Pediatr. Dev. Pathol., 5, 448-464.
41. Yamamoto, Y., Jones, K.A., Mak, B.C., Muehlenbachs, A. and Yeung, R.S. (2002) Multicompartmental distribution of the tuberous sclerosis gene products, hamartin and tuberin. Arch. Biochem. Biophys., 404 210-217.
42. Clements, D., Mayer, R.J. and Johnson, S.R. (2007) Subcellular distribution of the TSC2 gene product tuberin in human airway smooth muscle cells is driven by multiple localization sequences and is cell-cycle dependent. Am. J. Physiol. Lung Cell. Mol. Physiol., 292, L258-L266.
43. Rosner, M., Freilinger, A. and Hengstschlager, M. (2007) Akt regulates nuclear/cytoplasmic localization of tuberin. Oncogene, 26, 521-531.
44. York, B., Lou, D. and Noonan, D.J. (2006) Tuberin nuclear localization can be regulated by phosphorylation of its carboxyl terminus. Mol. Cancer Res., 4, 885-897.
45. Ali, J.B., Sepp, T., Ward, S., Green, A.J. and Yates, J.R. (1998) Mutations in the TSC1 gene account for a minority of patients with tuberous sclerosis. J. Med. Genet., 35, 969-972.
46. Kwiatkowska, J., Jozwiak, S., Hall, F., Henske, E.P., Haines, J.L., McNamara, P., Braiser, J., Wigowska-Sowinska, J., Kasprzyk-Obara, J., Short, M.P. et al. (1999) Comprehensive mutational analysis of the TSC1 gene: Observations on frequency of mutation, associated features, and norpenetrance. Ann. Hum. Genet., 62, 277-285.
47. Niida, Y., Lawrence-Smith, N., Banwell, A., Hammer, E., Lewis, J., Beauchamp, R.L., Sims, K., Ramesh, V. and Ozelius, L. (1999) Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis. Hum. Mutat., 14, 412-422.
48. Young, J. and Povey, S. (1998) The genetic basis of tuberous sclerosis. Mol. Med. Today, 4, 313-319.
49. Dabora, S.L., Jozwiak, S., Franz, D.N., Roberts, P.S., Nieto, A., Chung, J., Choy, Y.S., Reeve, M.P., Thiele, E., Egelhoff, J.C. et al. (2001) Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet., 68, 64-80.
50. Jones, A.C., Shyamsundar, M.M., Thomas, M.W., Maynard, J., Idziaszczyk, S., Tomkins, S., Sampson, J.R. and Cheadle, J.P. (1999) Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am. J. Hum. Genet., 64, 1305-1315.
51. van Slegtenhorst, M., Verhoef, S., Tempelaars, A., Bakker, L., Wang, Q., Wessels, M., Bakker, R., Nellist, M., Lindhout, D., Halley, D. et al. (1999) Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: No evidence for genotype-phenotype correlation. J. Med. Genet., 36, 285-289.
52. Nellist, M., Verhaaf, B., Goedbloed, M.A., Reuser, A.J., van den Ouweland, A.M. and Halley, D.J. (2001) TSC2 missense mutations inhibit taberin phosphorylation and prevent formation of the tuberin-hamartin complex. Hum. Mol. Genet., 10, 2889-2898.
53. Srebrow, A. and Kornblihtt, A.R. (2006) The connection between splicing and cancer. J. Cell Sci., 119, 2635-2641.
54. Buratti, E., Baralle, M. and Baralle, F.E. (2006) Defective splicing, disease and therapy: Searching for master checkpoints in exon definition. Nucleic Acids Res., 34, 3494-3510.
55. Krawczak, M., Thomas, N.S., Hundrieser, B., Mort, M., Wittig, M., Hampe, J. and Cooper, D.N. (2007) Single base-pair substitutions in exon-intron junctions of human genes: Nature, distribution, and consequences for mRNA splicing. Hum. Mutat., 28, 150-158.
56. Baud, E., Catilina, P. and Bignon, Y.J. (1999) p16 involvement in primary bladder tumors: Analysis of deletions and mutations. Int. J. Oncol., 14, 441-445.
57. Orlow, I., Lacombe, L., Hannon, G.J., Serrano, M., Pellicer, I., Dalbagni, G., Reuter, V.E., Zhang, Z.F., Beach, D. and Cordon-Cardo, C. (1995) Deletion of the p16 and p15 genes in human bladder tumors. J. Natl Cancer Inst., 87, 1524-1529.
58. Greenman, C., Stephens, P., Smith, R., Dalgliesh, G.L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C. et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature, 446, 153-158.
59. Cliby, W., Ritland, S., Hartmann, L., Dodson, M., Halling, K.C., Keeney, G., Podratz, K.C. and Jenkins, R.B. (1993) Human epithelial ovarian cancer allelotype. Cancer Res., 53, 2393-2398.
60. Devlin, J., Elder, P.A., Gabra, H., Steel, C.M. and Knowles, M.A. (1996) High frequency of chromosome 9 deletion in ovarian cancer: Evidence for three tumour-suppressor loci. Br. J. Cancer, 73, 420-423.
61. Girard, L., Zochbauer-Muller, S., Virmani, A.K., Gazdar, A.F. and Minna, J.D. (2000) Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res., 60, 4894-4906.
62. Lo, K.W., Teo, P.M., Hui, A.B., To, K.F., Tsang, Y.S., Chan, S.Y., Mak, K.F., Lee, J.C. and Huang, D.P. (2000) High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res., 60, 3348-3353.
63. Okada, S., Tsuda, H., Takarabe, T., Yoshikawa, H., Taketani, Y. and Hirohashi, S. (2002) Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types. Jpn. J. Cancer Res., 93, 798-806.
64. Suzuki, K., Ogura, T., Yokose, T., Nagai, K., Mukai, K., Kodama, T., Nishiwaki, Y. and Esumi, H. (1999) Loss of heterozygosity in the tuberous sclerosis gene associated regions in adenocarcinoma of the lung accompanied by multiple atypical adenomatous hyperplasia. Int. J. Cancer, 79, 384-389.
65. Wistuba, I.L., Maitra, A., Carrasco, R., Tang, M., Troncoso, P., Minna, J.D. and Gazdar, A.F. (2002) High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma. Br. J. Cancer, 87, 432-440.
66. Parry, L., Maynard, J.H., Patel, A., Clifford, S.C., Morrissey, C., Maher, E.R., Cheadle, J.P. and Sampson, J.R. (2001) Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. Br. J. Cancer, 85, 1226-1230.
67. Parry, L., Maynard, J.H., Patel, A., Hodges, A.K., von Deimling, A., Sampson, J.R. and Cheadle, J.P. (2000) Molecular analysis of the TSC1 and TSC2 tumour suppressor genes in sporadic glial and glioneuronal tumours. Hum. Genet., 107, 350-356.
68. Takamochi, K., Ogura, T., Suzuki, K., Kawasaki, H., Kurashima, Y., Yokose, T., Ochiai, A., Nagai, K., Nishiwaki, Y. and Esumi, H. (2001) Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. Am. J. Pathol., 159, 1941-1948.
69. Takamochi, K., Ogura, T., Yokose, T., Ochiai, A., Nagai, K., Nishiwaki, Y., Suzuki, K. and Esumi, H. (2004) Molecular analysis of the TSC1 gene in adevocarcinoma of the lung. Lung Cancer, 46, 271-281.
70. Fang, Y., Guan, X., Guo, Y., Sham, J., Deng, M., Liang, Q., Li, H., Zhang, H., Zhou, H. and Trent, J. (2001) Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization. Genes Chromosomes Cancer, 30, 254-260.
71. Nakayama, K., Konno, M., Kanzaki, A., Morikawa, T., Miyashita, H., Fujioka, T., Uchida, T., Miyazaki, K., Takao, S., Aikou, T. et al. (2001) Allelotype analysis of gallbladder carcinoma associated with anomalous junction of pancreaticobiliary duct. Cancer Lett., 166, 135-141.
72. Sarkar, S., Julicher, K.P., Burger, M.S., Della Valle, V., Larsen, C.J., Yeager, T.R., Grossman, T.B., Nickells, R.W., Protzel, C., Jarrard, D.F. et al. (2000) Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res., 60, 3862-3871.
73. Yeager, T.R., DeVries, S., Jarrard, D.F., Kao, C., Nakada, S.Y., Moon, T.D., Bruskewitz, R., Stadler, W.M., Meisner, L.F., Gilchrist, K.W. et al. (1998) Overcoming cellular senescence in human cancer pathogenesis. Genes Dev., 12, 163-174.
74. Bean, M.A., Pees, H., Fogh, J.E., Grabstald, H. and Oettgen, H.F. (1974) Cytotoxicity of lymphocytes from patients with cancer of the urinary bladder: Detection by a 3-H-proline microcytotoxicity test. Int. J. Cancer, 14, 186-197.
75. Southgate, J., Hutton, K.A., Thomas, D.F. and Trejdosiewicz, L.K. (1994) Normal human urothelial cells in vitro: Proliferation and induction of stratification. Lab. Invest., 71, 583-594.
76. Chapman, E.J., Hurst, C.D., Pitt, E., Chambers, P., Aveyard, J.S. and Knowles, M.A. (2006) Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene 25, 5037-5045.